Letter to the EditorEnoxaparin in unstable angina patients with renal failure
References (6)
- et al.
Assessment of the treatment of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-Essence meta-analysis
Circulation
(1999) - et al.
Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)
Thromb Haemost
(1998) Dose-ranging trial of enoxaparin for unstable angina patients: results of TIMI 11A
J Am Coll Cardiol
(1997)
There are more references available in the full text version of this article.
Cited by (92)
What are the special features of treatment in “fragile” patients (elderly, renal failure)
2021, Revue des Maladies RespiratoiresOptimal time for catheterization in NSTE-ACS patients with impaired renal function: Insights from the ABOARD Study
2013, International Journal of CardiologyHematoma of the rectus abdominis muscle in patients treated with low-molecular-weight heparin: Four clinical cases
2011, Revista Clinica EspanolaStudy of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function
2009, Journal of Thrombosis and HaemostasisEfficacy and Safety of Fondaparinux and Enoxaparin for Acute Coronary Syndromes in CKD
2008, American Journal of Kidney DiseasesThe Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial
2007, Journal of the American College of Cardiology
Copyright © 2001 Elsevier Science Ireland Ltd. All rights reserved.